Table 3B.
Relationships between the expression of immune-related genes and the clinicopathological factors in esophageal adenocarcinoma.
| ID | Gender (male/female) | Tumor stage (III-IV/I-II) | T (T3–4/T1-2) | M (M1/M0) | N (N1-3/N0) | Fustat (1/0) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| t | p | t | p | t | p | t | p | t | p | t | p | |
| ULBP1 | 0.888 | (0.403) | -0.264 | (0.793) | -0.15 | (0.881) | 0.577 | (0.577) | 0.399 | (0.694) | -0.222 | (0.825) |
| IL1B | 2.252 | (0.043) | -0.928 | (0.360) | -0.51 | (0.613) | -1.769 | (0.150) | 0.692 | (0.492) | -1.617 | (0.114) |
| FABP2 | -0.153 | (0.880) | -0.19 | (0.850) | 0.334 | (0.740) | 1.304 | (0.213) | -0.07 | (0.944) | -0.682 | (0.499) |
| MAPT | -2.354 | (0.023) | -0.996 | (0.327) | -0.902 | (0.373) | 2.05 | (0.046) | -2.001 | (0.052) | 0.059 | (0.953) |
| CST4 | -1.364 | (0.178) | -1.625 | (0.116) | -1.719 | (0.096) | 0.626 | (0.542) | -1.901 | (0.065) | -1.139 | (0.265) |
| CACYBP | -1.47 | (0.151) | -2.139 | (0.039) | -1.545 | (0.130) | -1.284 | (0.263) | -2.292 | (0.026) | -2.057 | (0.047) |
| DLL4 | -0.058 | (0.955) | -1.598 | (0.120) | -1.082 | (0.285) | 0.349 | (0.738) | -2.028 | (0.048) | -1.833 | (0.075) |
| IL17A | 1.063 | (0.321) | -0.166 | (0.868) | 0.156 | (0.877) | -0.792 | (0.467) | -1.194 | (0.238) | -2.042 | (0.051) |
| PGF | 0.199 | (0.844) | -1.619 | (0.116) | -1.64 | (0.110) | -0.203 | (0.847) | -1.914 | (0.061) | -1.69 | (0.101) |
| TNFSF18 | -2.159 | (0.041) | -1.472 | (0.149) | -2.316 | (0.027) | -0.368 | (0.731) | -0.511 | (0.613) | -0.552 | (0.584) |
| OXTR | -2.087 | (0.042) | -2.003 | (0.056) | -1.718 | (0.096) | 0.005 | (0.996) | -2.005 | (0.052) | -1.589 | (0.124) |
| RiskScore | -1.619 | (0.112) | -2.181 | (0.039) | -2.091 | (0.046) | -0.719 | (0.508) | -2.254 | (0.031) | -2.105 | (0.045) |
*The value in bold is statistically significant.